| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
Neomycin sulphate B targets bacterial ribosomes, inhibiting protein synthesis in susceptible bacteria. It also targets RNase P cleavage activity (Ki = 35 μM) and hammerhead ribozyme (Ki = 13.5 μM). As an aminoglycoside antibiotic, it binds to the 30S ribosomal subunit, causing misreading of the genetic code and inhibition of protein synthesis. It is a potent antibiotic with broad-spectrum activity.
|
|---|---|
| ln Vitro |
Framycetin suLfate (also known as Neomycin BsuLfate or Fradiomycin BsuLfate) has an inhibitory impact on RNase P RNA that is sensitive to pH value; hence, lowering pH will reduce the inhibitory effect of other systems [1]. The novel antibiotics 5-Azide Framycetin Sulfate B and Sulfate specifically prevent the synthesis of mature miRNAs, interact with cytokines, and effectively inhibit HCC cell lines [2]. The primary homologous target of framycetin suLfate is the decoding site of 16S rRNA; however, it also binds to the Rev response element, group I intron, and hammerhead ribozyme in HIV-1, inhibiting their biological functions [sulfate new Mycin induces misreading of genetic codes during translation and inhibits various ribozymes]. Framycetin suLfate is related to the structural motif of RNA and the DNA sequence motif of it. The 16 S rRNA region spanning from 1400 to 1500 is the ribosome target location [4].
In vitro, Neomycin sulphate B inhibits RNase P cleavage activity with a Ki of 35 μM. It inhibits hammerhead ribozyme with a Ki of 13.5 μM. As an aminoglycoside antibiotic, it has potent antibacterial activity against a wide range of bacteria. Detailed in vitro data are available in the primary literature. The compound is a well-characterized antibiotic. |
| ln Vivo |
In vivo, Neomycin sulphate B is used as an antibiotic for the treatment of bacterial infections. It can enhance the effectiveness of topical antibacterial treatment of adenoiditis. It is also used in burn therapy. The compound is used in research on liver encephalopathy and enteropathogenic E. coli infection. It is a clinically used antibiotic.
|
| Enzyme Assay |
In vitro antibacterial susceptibility testing for Neomycin sulphate B typically uses broth microdilution or agar diffusion methods according to CLSI guidelines. The compound is dissolved in water or appropriate buffer and serially diluted in growth medium. Bacterial cultures are inoculated at standard densities and incubated at 37°C for 18-24 hours. Minimum inhibitory concentration (MIC) is determined as the lowest concentration inhibiting visible growth. RNase P cleavage activity assays use the enzyme and substrate with varying compound concentrations. Ki values are calculated from dose-response curves. Controls include vehicle and reference antibiotics.
|
| Cell Assay |
For cell-based assays, bacterial cultures or eukaryotic cell lines are used. For antibacterial studies, bacteria are cultured in appropriate medium and treated with Neomycin sulphate B at various concentrations. Bacterial growth is monitored by optical density or colony counting. For RNase P or ribozyme studies, cell-free systems or cell lysates are used. Cell viability in eukaryotic cells is assessed by MTT or CellTiter-Glo. All treatments include vehicle controls and are performed in triplicate.
|
| Animal Protocol |
In vivo, Neomycin sulphate B is typically administered orally or topically. For animal studies, rodents are dosed orally or via other routes. For infection models, animals are infected with bacteria and treated with the antibiotic. Endpoints include bacterial load reduction, survival, and tissue histology. Blood samples are collected for pharmacokinetic analysis. All procedures follow institutional guidelines.
|
| ADME/Pharmacokinetics |
Neomycin sulphate B (MW 712.72, C₂₃H₄₆N₆O₁₃·3H₂SO₄) is an aminoglycoside antibiotic. The compound is a white or yellowish-white powder that is hygroscopic. It has a melting point of >160°C (dec.). It is soluble in water. Detailed pharmacokinetic parameters are available from pharmacological literature. The compound is a clinically used antibiotic.
|
| Toxicity/Toxicokinetics |
Neomycin sulphate B is a clinically used antibiotic with an established safety profile. It is used topically, orally, and for bowel preparation. Common side effects include nephrotoxicity and ototoxicity with systemic use. It is contraindicated in patients with renal impairment and hearing loss. The compound is available as a pharmaceutical product.
|
| References |
[1]. N E Mikkelsen, et al. Inhibition of RNase P RNA Cleavage by Aminoglycosides. Proc Natl Acad Sci U S A. 1999 May 25;96(11):6155-60.
[2]. Childs-Disney JL, et al. Small Molecule Targeting of a MicroRNA Associated with Hepatocellular Carcinoma. ACS Chem Biol. 2016 Feb 19;11(2):375-80. [3]. Stampfl S, et al. Monovalent ion dependence of neomycin B binding to an RNA aptamer characterized by spectroscopic methods. Chembiochem. 2007 Jul 9;8(10):1137-45. [4]. Hoch I, et al. Antibiotic inhibition of RNA catalysis: neomycin B binds to the catalytic core of the td group I intron displacing essential metal ions. J Mol Biol. 1998 Sep 25;282(3):557-69. |
| Additional Infomation |
Neomycin sulfate B is the sulfate form of neomycin B and is also a component of neomycin sulfate. It contains flammycin. Neomycin sulfate is a broad-spectrum aminoglycoside antibiotic derived from Streptomyces fradiae and possesses antibacterial activity. Neomycin is an antibiotic complex composed of three components: two isoform components, B and C, are the active ingredient, and neomycin A is the minor component. Neomycin irreversibly binds to the 16S rRNA and S12 protein of the bacterial 30S ribosomal subunit. Therefore, the drug interferes with the assembly of the initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. Furthermore, neomycin induces misreading of the mRNA template, leading to frameshift translation and premature termination of translation. This ultimately results in bacterial cell death.
Flammoxetine sulfate is the sulfate form of flammoxetine, an aminoglycoside antibiotic isolated from Streptomyces lavendulae (decaris). Its main component is neomycin B, which has broad-spectrum antibacterial activity. Flammoxetine is primarily used as a topical preparation and is poorly absorbed. Parenteral administration can cause nephrotoxicity and ototoxicity. Neomycin is a component produced by Streptomyces fradiae. Upon hydrolysis, it yields neomycin and neobiotic B. (Excerpt from Merck Index, 11th edition) Neomycin sulphate B (Framycetin sulfate) is a clinically used aminoglycoside antibiotic. It is used topically for the treatment of skin infections, orally for bowel preparation, and in research on liver encephalopathy and enteropathogenic E. coli infection. It also inhibits RNase P and hammerhead ribozyme. It is available as a pharmaceutical product and from chemical suppliers for research purposes. Its mechanism involves ribosomal binding and inhibition of protein synthesis. |
| Molecular Formula |
C23H48N6O17S
|
|---|---|
| Molecular Weight |
712.72
|
| Exact Mass |
712.28
|
| CAS # |
4146-30-9
|
| Related CAS # |
Framycetin;119-04-0
|
| PubChem CID |
197162
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
927.1ºC at 760 mmHg
|
| Flash Point |
514.5ºC
|
| Hydrogen Bond Donor Count |
15
|
| Hydrogen Bond Acceptor Count |
23
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
47
|
| Complexity |
953
|
| Defined Atom Stereocenter Count |
19
|
| SMILES |
C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@@H](CN)O2)O)O)N)O[C@H]3[C@@H]([C@@H]([C@@H](CO)O3)O[C@@H]4[C@@H]([C@H]([C@@H]([C@H](CN)O4)O)O)N)O)O)N.OS(=O)(=O)O.OS(=O)(=O)O.OS(=O)(=O)O
|
| InChi Key |
KWBUARAINLGYMG-JGMIRXPNSA-N
|
| InChi Code |
InChI=1S/C23H46N6O13.3H2O4S/c24-2-7-13(32)15(34)10(28)21(37-7)40-18-6(27)1-5(26)12(31)20(18)42-23-17(36)19(9(4-30)39-23)41-22-11(29)16(35)14(33)8(3-25)38-22;3*1-5(2,3)4/h5-23,30-36H,1-4,24-29H2;3*(H2,1,2,3,4)/t5-,6+,7-,8+,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+;;;/m1.../s1
|
| Chemical Name |
(2R,3R,4S,5S,6S)-5-amino-2-(aminomethyl)-6-(((2R,3S,4R,5S)-5-(((1R,2R,3S,5R,6S)-3,5-diamino-2-(((2R,3R,4R,5S,6R)-3-amino-6-(aminomethyl)-4,5-dihydroxytetrahydro-2H-pyran-2-yl)oxy)-6-hydroxycyclohexyl)oxy)-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yl)oxy)tetrahydro-2H-pyran-3,4-diol sulfate
|
| Synonyms |
Neomycin sulphate B Framycetin sulphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~250 mg/mL (~275.06 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (55.01 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4031 mL | 7.0154 mL | 14.0308 mL | |
| 5 mM | 0.2806 mL | 1.4031 mL | 2.8062 mL | |
| 10 mM | 0.1403 mL | 0.7015 mL | 1.4031 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
